ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

RVA Reva Medical Inc

0.17
0.00 (0.00%)
13 May 2024 - Closed
Delayed by 20 minutes
Share Name Share Symbol Market Type
Reva Medical Inc ASX:RVA Australian Stock Exchange Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.17 0.175 0.19 0.00 01:00:00

REVA to Present at 24th Annual Piper Jaffray Healthcare Conference

21/11/2012 1:49am

GlobeNewswire Inc.


Reva Medical (ASX:RVA)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Reva Medical Charts.

REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") is pleased to announce that its Chairman and CEO, Robert Stockman, is presenting at the 24th Annual Piper Jaffray Healthcare Conference at 2:30 p.m. US EST on Tuesday, November 27, 2012. The conference is being held November 27 and 28, 2012, at The New York Palace in New York City.

The information contained in the presentation has been previously disclosed. Copies of REVA's public presentations, which include recent disclosures, may be accessed under the Investor Relations section of the REVA website at www.revamedical.com.

About REVA

REVA is a development stage medical device company incorporated in Delaware, USA, that is focused on the development and eventual commercialization of its proprietary bioresorbable stent products. REVA's initial product, the ReZolveƒscaffold, which is in a clinical study phase, combines REVA's proprietary stent design with a proprietary polymer that is metabolized and cleared from the body. The ReZolve scaffold is designed to offer full x-ray visibility, clinically relevant sizing, and a controlled and safe resorption rate. In addition, by early encapsulation of the stent in the artery tissue coupled with the loss of scaffold structure over time, the ReZolve scaffold may reduce the incidence of late forming blood clots or otherwise reduce long-term disease progression, potential benefits of bioresorbable scaffolds that have yet to be proven. REVA will require clinical results and regulatory approval before it can begin selling the ReZolve scaffold.

The REVA Medical, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8505

CONTACT: United States
         Investor and Media Enquiries:
         Cheryl Liberatore
         Director, Investor Relations and Marketing
         REVA Medical, Inc.
         +1 858 966-3045
         
         Australia
         Investor Enquiries:
         Kim Jacobs or Alan Taylor
         Inteq Limited
         +61 2 9231 3322
         
         Media Enquiries:
         Haley Price or Rebecca Wilson
         Buchan Consulting
         +61 3 9866 4722

1 Year Reva Medical Chart

1 Year Reva Medical Chart

1 Month Reva Medical Chart

1 Month Reva Medical Chart

Your Recent History

Delayed Upgrade Clock